AMGEN PRESENTS NEW REPATHA® (EVOLOCUMAB) DATA AT AHA 2022
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Amgen (AMGN) data supports long-term growth potential says analyst
November 8, 2022 10:37 AM ESTAmgen (NASDAQ: AMGN) reported new analysis from its Phase 3 FOURIER and FOURIER open label extension (OLE) studies of Repatha on Tuesday, stating that the data reinforces long-term efficacy and the consistent safety profile.
Amgen shares are up more than 5% following the... More
Amgen (AMGN) PT Raised to $325 at Jefferies Following AMG-133 Update
November 8, 2022 8:16 AM ESTJefferies analyst Michael Yee raised the price target on Amgen (NASDAQ: AMGN) to $325.00 (from $300.00) while maintaining a Buy rating.
The analyst commented, "AMGN update looks positive and consistent w/ our Buy, with valuation likely to go up with AMG-133 for obesity... More
